ArticleApplied biochemistry and biotechnology2026
Model-Guided Optimization of a Low-Serum Medium for Madin-Darby Canine Kidney Cells Using a Kolmogorov-Arnold Network and Bayesian Optimization.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Madin-Darby canine kidney (MDCK) cells are important hosts for cell culture-based viral vaccine production, but fetal bovine serum (FBS) supplementation increases cost, batch variability, adventitious-agent risk, and regulatory burden. This study developed a 2% FBS low-serum medium optimization workflow for MDCK cells by integrating design of experiments (DoE) with interpretable machine learning. A Plackett-Burman (PB) design screened 27 nutritional components and identified seven factors that significantly affected proliferation. L-glutamine, L-asparagine, and L-tyrosine showed positive effects and were further optimized using a three-factor Box-Behnken design (BBD). A Kolmogorov-Arnold network (KAN) modeled the nonlinear proliferation response, and its response function served as the objective function for Bayesian optimization (BO). After two KAN-BO validation cycles, the optimized formulation contained 292.30 mg/L L-glutamine, 54.36 mg/L L-tyrosine, and 11.34 mg/L L-asparagine. The predicted relative proliferation rate was 159.38%, in close agreement with the experimental value of 158.63 ± 1.70%. Compared with Baseline medium, Optimized medium enhanced MDCK cell proliferation while maintaining typical adherent epithelial-like morphology and high viability. In H1N1 BVR-26 production assays, Optimized medium achieved a peak titer of 3.50 ± 0.05 log
Indexed as
Identifiers
42490010What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.